Traders bought shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on weakness during trading hours on Friday following a weaker than expected earnings announcement. $49.05 million flowed into the stock on the tick-up and $31.62 million flowed out of the stock on the tick-down, for a money net flow of $17.43 million into the stock. Of all stocks tracked, Alnylam Pharmaceuticals had the 24th highest net in-flow for the day. Alnylam Pharmaceuticals traded down ($0.40) for the day and closed at $115.92The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.38) by ($0.10). The firm had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The company’s quarterly revenue was up 116.6% compared to the same quarter last year. During the same period last year, the firm earned ($1.32) EPS.

Several research analysts have recently issued reports on ALNY shares. B. Riley cut their price target on Alnylam Pharmaceuticals to $220.00 and set a “buy” rating for the company in a research note on Wednesday, November 8th. Jefferies Group reaffirmed a “buy” rating and set a $156.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday. Leerink Swann lifted their price target on Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the stock a “market perform” rating in a research note on Thursday, January 25th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $14.71 price target (down previously from $188.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, November 2nd. Finally, BidaskClub downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $126.98.

In other news, SVP Laurie Keating sold 6,249 shares of the company’s stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total transaction of $757,378.80. Following the completion of the transaction, the senior vice president now owns 17,749 shares of the company’s stock, valued at approximately $2,151,178.80. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO John Maraganore sold 73,415 shares of the company’s stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $130.90, for a total transaction of $9,610,023.50. Following the transaction, the chief executive officer now directly owns 223,125 shares of the company’s stock, valued at approximately $29,207,062.50. The disclosure for this sale can be found here. Insiders sold a total of 220,409 shares of company stock valued at $28,667,017 in the last three months. 4.30% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of ALNY. Prudential Financial Inc. increased its stake in shares of Alnylam Pharmaceuticals by 4.8% during the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after acquiring an additional 200 shares during the last quarter. Northern Trust Corp increased its stake in shares of Alnylam Pharmaceuticals by 5.0% during the 2nd quarter. Northern Trust Corp now owns 377,020 shares of the biopharmaceutical company’s stock valued at $30,072,000 after acquiring an additional 17,862 shares during the last quarter. Suntrust Banks Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $320,000. Parametric Portfolio Associates LLC increased its stake in shares of Alnylam Pharmaceuticals by 8.2% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 64,943 shares of the biopharmaceutical company’s stock valued at $5,180,000 after acquiring an additional 4,913 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Alnylam Pharmaceuticals by 59.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 179,429 shares of the biopharmaceutical company’s stock valued at $14,311,000 after acquiring an additional 66,651 shares during the last quarter. 88.39% of the stock is owned by institutional investors.

The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $11,400.00, a P/E ratio of -22.08 and a beta of 2.68.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2018/02/10/traders-buy-shares-of-alnylam-pharmaceuticals-alny-on-weakness-on-disappointing-earnings.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.